EP3193869 - PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES [Right-click to bookmark this link] | Status | The application has been refused Status updated on 19.02.2021 Database last updated on 24.08.2024 | |
Former | Examination is in progress Status updated on 31.08.2018 | ||
Former | Request for examination was made Status updated on 23.06.2017 | ||
Former | The international publication has been made Status updated on 24.02.2017 | Most recent event Tooltip | 19.02.2021 | Refusal of application | published on 24.03.2021 [2021/12] | Applicant(s) | For all designated states Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Ludwig-Erhard-Allee 2 53175 Bonn / DE | For all designated states Klinikum rechts der Isar der Technischen Universität München Ismaninger Straße 22 81675 München / DE | [2017/30] | Inventor(s) | 01 /
HÖGLINGER, Günter Egenhofenstraße 1e 82152 Planegg / DE | 02 /
BRUCH, Julius Zittelstraße 5 80796 München / DE | 03 /
RÖSLER, Thomas Irmonherstraße 6 81241 München / DE | [2017/30] | Representative(s) | Gosmann, Martin, et al Gospat-Patentanwalt Schlägerstraße 23 30171 Hannover / DE | [2017/30] | Application number, filing date | 15762491.7 | 14.08.2015 | [2017/30] | WO2015EP68734 | Priority number, date | EP20140181071 | 14.08.2014 Original published format: EP 14181071 | [2017/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016024010 | Date: | 18.02.2016 | Language: | EN | [2016/07] | Type: | A1 Application with search report | No.: | EP3193869 | Date: | 26.07.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.02.2016 takes the place of the publication of the European patent application. | [2017/30] | Search report(s) | International search report - published on: | EP | 18.02.2016 | Classification | IPC: | A61K31/4704, A61P25/28 | [2017/30] | CPC: |
A61K31/195 (EP,US);
A61K31/415 (EP,US);
A61K31/4152 (EP,US);
A61K31/42 (EP,US);
A61K31/4704 (EP,US);
A61K31/4709 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/30] | Title | German: | PERK-AKTIVATOR ZUR BEHANDLUNG NEURODEGENERATIVER ERKRANKUNGEN | [2017/30] | English: | PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | [2017/30] | French: | ACTIVATEUR DU SIGNAL PERK POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES | [2017/30] | Entry into regional phase | 23.02.2017 | National basic fee paid | 23.02.2017 | Designation fee(s) paid | 23.02.2017 | Examination fee paid | Examination procedure | 23.02.2017 | Examination requested [2017/30] | 23.02.2017 | Date on which the examining division has become responsible | 29.09.2017 | Amendment by applicant (claims and/or description) | 29.08.2018 | Despatch of a communication from the examining division (Time limit: M06) | 15.03.2019 | Reply to a communication from the examining division | 08.07.2019 | Invitation to indicate the basis for amendments (Time limit: M01) | 12.08.2019 | Reply to an invitation to indicate the basis for amendments | 14.11.2019 | Despatch of a communication from the examining division (Time limit: M02) | 24.01.2020 | Reply to a communication from the examining division | 26.10.2020 | Cancellation of oral proceeding that was planned for 23.11.2020 | 05.11.2020 | Despatch of communication that the application is refused, reason: substantive examination [2021/12] | 15.11.2020 | Application refused, date of legal effect [2021/12] | 23.11.2020 | Date of oral proceedings (cancelled) | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 15.03.2019 | Request for further processing filed | 15.03.2019 | Full payment received (date of receipt of payment) Request granted | 26.03.2019 | Decision despatched | Fees paid | Renewal fee | 31.08.2017 | Renewal fee patent year 03 | 31.08.2018 | Renewal fee patent year 04 | 02.09.2019 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.08.2020 | 06   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2013192165 (UNIV KANSAS [US], et al) [X] 1-11,13-19 * paragraphs [0014] - [0021] *; | [XD] - STOCKWELL SIMON R ET AL, "Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling.", PLOS ONE 2012, (2012), vol. 7, no. 1, ISSN 1932-6203, pages 1 - 16, XP002731158 [XD] 1-19 * page 12, column l, lines 55-64 * DOI: http://dx.doi.org/10.1371/journal.pone.0028568 | [X] - LEE DO YEON ET AL, "Activation of PERK signaling attenuates Abeta-mediated ER stress.", PLOS ONE 2010, (2010), vol. 5, no. 5, ISSN 1932-6203, pages 1 - 8, XP002731159 [X] 1-11,13-19 * the whole document * DOI: http://dx.doi.org/10.1371/journal.pone.0010489 | Examination | - KOVACS ET AL., NERVENARZT, (20180817), vol. 89, pages 1083 - 1094 | - GÖTZ ET AL., ANNU. REV. PATHOL. MECH. DIS., (20181024), vol. 14, pages 239 - 261 | - WILLIAMS, INTERNAL MEDICINE JOURNAL, (2006), vol. 36, pages 652 - 660 | by applicant | WO2013192165 | - AXTEN, J. M. ET AL., J MED CHEM, (2012), vol. 55, no. 16, pages 7193 - 207 | - B'CHIR, W. ET AL., NUCLEIC ACIDS RES, (2013), vol. 41, no. 16, pages 7683 - 99 | - BOUMAN, L. ET AL., CELL DEATH DIFFER, (2011), vol. 18, no. 5, pages 769 - 82 | - BOYCE, M. ET AL., SCIENCE, (2005), vol. 307, no. 5711, pages 935 - 9 | - BOXER ET AL., LANCET NEUROL, (2014), vol. 13, no. 7, pages 676 - 85 | - BRUCH, J ET AL., J NEUROPATHOL EXP NEUROL., (2015), vol. 74, no. 8, pages 850 - 7 | - BUEE-SCHERRER, V. ET AL., BRAIN RES MOL BRAIN RES, (1996), vol. 39, no. 1-2, pages 79 - 88 | - CAILLIEREZ, R. ET AL., MOL THER, (2013), vol. 21, no. 7, pages 1358 - 68 | - CULLINAN, S. B. ET AL., MOL CELL BIOL, (2003), vol. 23, no. 20, pages 7198 - 209 | - ESCOBAR-KHONDIKER, M. ET AL., J NEUROSCI, (2007), vol. 27, no. 29, pages 7827 - 37 | - GANI, A. R. ET AL., ARCH BIOCHEM BIOPHVS, (2015), vol. 568, pages 8 - 15 | - GIBSON, D. G. ET AL., NAT METHODS, (2009), vol. 6, no. 5, pages 343 - 5 | - HETZ, C. ET AL., NAT REV NEUROSCI, (2014), vol. 15, no. 4, pages 233 - 49 | - HOGLINGER, G. U. ET AL., NAT GENET, (2011), vol. 43, no. 7, pages 699 - 705 | - ISHIZAWA, T. ET AL., J NEUROPATHOL EXP NEUROL, (2003), vol. 62, no. 4, pages 389 - 97 | - JICHA, G. A. ET AL., J NEUROSCI RES, (1997), vol. 48, no. 2, pages 128 - 32 | - KUHN, P. H. ET AL., EMBO J, (2010), vol. 29, no. 17, pages 3020 - 32 | - LEE DO, Y. ET AL., PLOS ONE, (2010), vol. 5, no. 5, page E10489 | - LIU, F. ET AL., MOL NEURODEQENER, (2008), vol. 3, page 8 | - LOEWEN, C. A ET AL., PLOS ONE, (2010), vol. 5, no. 9 | - LOTHARIUS, J. ET AL., J NEUROSCI, (2005), vol. 25, no. 27, pages 6329 - 42 | - MA, T. ET AL., NAT NEUROSCI, (2013), vol. 16, no. 9, pages 1299 - 305 | - MORENO, J. A. ET AL., SCI TRANSL MED, (2013), vol. 5, no. 206, page 206RA138 | - OZASA, R. ET AL., CELL STRUCT FUNCT, (2013), vol. 38, no. 2, pages 183 - 95 | - PYTEL, D. ET AL., J BIOMOL SCREEN, (2014), vol. 19, no. 7, pages 1024 - 34 | - SCHEPER, W. ET AL., SCI TRANSL MED, (2013), vol. 5, no. 206, page 206FS37 | - STOCKWELL, S. R. ET AL., PLOS ONE, (2012), vol. 7, no. 1, page E28568 | - STUTZBACH, L. D. ET AL., ACTA NEUROPATHOL COMMUN, (2013), vol. 1, page 31 | - TOLOSA ET AL., MOV DISORD., (2014), vol. 29, no. 4, pages 470 - 8 | - VACCARO, A. ET AL., NEUROBIOL DIS, (2013), vol. 55, pages 64 - 75 | - VAN DER HARG, J. M. ET AL., CELL DEATH DIS, (2014), vol. 5, page E1393 | - WIN, S. ET AL., J HEPATOL, (2015), vol. 62, no. 6, pages 1367 - 74 | - WU, H. L. ET AL., CARDIOVASC RES, (2009), vol. 81, no. 1, pages 148 - 58 | - XIE, W. ET AL., PLOS ONE, (2015), vol. 10, no. 3, page E0119738 | - XU, H. ET AL., NEUROPATHOL APPL NEUROBIOL, (2014), vol. 40, no. 7, pages 833 - 43 | - YAN, Y. ET AL., BMC CANCER, (2010), vol. 10, page 445 | - YANG, L. ET AL., J BIOL CHEM, (2013), vol. 288, no. 19, pages 13631 - 8 | - ZHU, Y. ET AL., J NEUROSCI, (2008), vol. 28, no. 9, pages 2168 - 78 |